Biotechnology
Vaccine Was Safe and Well Tolerated at the Maximum Tolerated Dose Results Support Advancement of the Program into Phase 2 Development Combination of Keytruda® and the vaccine generated T cell responses and showed no major additional side effects, supporting plans for a Phase 2 neoadjuvant combination study in newly diagnosed breast cancer patients Excerpt from…
Early results from the Phase 1 inMMyCAR™ study demonstrate ongoing MRD-negative responses in all patients with a tolerable safety profile Robust CAR-T cell expansion occurred in the absence of preparative chemotherapy Persistent, memory CAR-T cells in all patients Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene…
VT-5006 is a first-in-class small molecule designed to precisely engage a validated peripheral target to delay onset and slow progression of Parkinson’s disease WOBURN, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) — Vertero Therapeutics, a clinical-stage biotechnology company breaking barriers in neurodegenerative disease treatment, today announced that it has initiated a Phase 1 study of its…
Company to launch only current registration trial with an immunotherapy in first-line pancreatic cancer in first half of 2026 Trial design allows flexibility to include an experimental arm with checkpoint inhibitor combination Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today…
78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in VK2735 Excerpt from the Press Release:v SAN DIEGO, Nov. 19, 2025 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and…
STMC-103H exhibited 64% reduction in the risk of atopic dermatitis in subjects who completed one year of treatment with strong and consistent effects across multiple efficacy endpoints and was safe and well-tolerated Excerpt from the Press Release: SAN CARLOS, Calif., Nov. 17, 2025 /PRNewswire/ — Siolta Therapeutics, a clinical-stage biotech company developing first-in-class live biotherapeutic…
– The collaboration will leverage General Proximity’s OmniTAC™ platform to identify and advance next generation induced proximity agents for high value oncology targets. – Induced proximity medicines, powered by the OmniTAC™ platform, enable precise modulation of disease-driving and traditionally undruggable proteins. – General Proximity will identify novel effector-target pairs that can be exploited through induced proximity medicines.…
Excerpt from the Press Release: EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies for cancer, today announced the publication of a peer-reviewed study titled “Antibody–Gamma/Delta T Cell Receptors Targeting GPC2 Regress Neuroblastoma with Low Antigen Density” in Cell Reports Medicine. The study, led by researchers at the National Cancer…
First Gene Therapy Trial for Angelman Syndrome -Orphan Drug Designation Granted for MVX-220 Excerpt from the Press Release: MIDDLETON, Mass., Nov. 6, 2025 /PRNewswire/ — MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the first patient has been dosed in the Phase 1/2…
Favorable early safety profile with preliminary clinical and mechanistic evidence of therapeutic activity in refractory rheumatoid arthritis Data to be presented in a late-breaking oral presentation today 8:00 a.m. CT at the 2025 American College of Rheumatology (ACR) Convergence Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif. & SEATTLE–(BUSINESS WIRE)–Sonoma Biotherapeutics, Inc., a clinical-stage…